<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Serum enzymes in patients with kidney failure</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Serum enzymes in patients with kidney failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Serum enzymes in patients with kidney failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil S Sanghani, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramesh Soundararajan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The serum enzymes of patients with end-stage kidney disease (ESKD) are commonly abnormal. This is due in part to the absence of kidney excretion and to the frequent presence of multiple comorbid conditions. Since the diagnosis of many diseases is based upon the detection of elevated levels of these enzymes, the accurate clinical assessment of the patient with ESKD is hampered by a paucity of knowledge concerning the serum concentrations of different enzymes in various disease states.</p><p>The use and significance of variations in the concentrations of serum enzymes in patients on dialysis will be reviewed here. A discussion of serum cardiac enzymes in patients with kidney failure is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1920.html" rel="external">"Cardiac troponins in patients with kidney disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">LIVER ENZYMES</span><span class="headingEndMark"> — </span>The serum enzymes most commonly used to help assess the diagnosis of hepatobiliary disease include the aminotransferases, alkaline phosphatase, and gamma-glutamyl transpeptidase (GGT).</p><p class="headingAnchor" id="H3"><span class="h2">Aminotransferases</span><span class="headingEndMark"> — </span>Serum concentrations of aspartate and alanine aminotransferase (AST [SGOT] and ALT [SGPT]) are routinely measured to assess liver function in patients with and without kidney failure. The aminotransferases are normally present in the circulation in low concentrations, usually &lt;40 int. units/L. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p>The concentrations of serum aminotransferases in both patients on chronic dialysis and those with nondialysis chronic kidney disease most commonly fall within the lower end of the range of normal values [<a href="#rid1">1-4</a>]. Although the exact cause is unknown, possible underlying reasons may be related to pyridoxine deficiency (pyridoxal phosphate is a necessary coenzyme for ALT and AST) [<a href="#rid5">5-7</a>] and/or the presence of an inhibitory substance in the uremic milieu [<a href="#rid1">1</a>].</p><p>In one study, for example, an increase in serum AST was observed after hemodialysis, suggesting the removal of an inhibitory substance with dialysis [<a href="#rid1">1</a>]. This effect was not due to urea alone, since the addition of urea to normal serum was not associated with a decline in the activity of AST. In this observational report, serum AST also positively correlated with the level of kidney function in a transplant recipient, declining in association with rejection or the need to resume hemodialysis.</p><p>The use of standard reference values for aminotransferases to help detect liver disease is therefore less useful in patients undergoing chronic dialysis therapy. In one study of over 500 patients on dialysis, standard cutoff values for aminotransferases were found to be poor indicators of active liver disease among hepatitis C antibody-positive individuals who were undergoing liver biopsy [<a href="#rid8">8</a>].</p><p>As a result, some investigators have suggested that, to increase the sensitivity of liver function tests among patients on dialysis, lower "normal" values of aminotransferases should be adopted [<a href="#rid9">9,10</a>]. In one study, the conventional upper limit of normal of 40 int. units/L for AST and ALT was changed to 24 and 17 int. units/L, respectively. To detect liver disease resulting from hepatitis B, these altered values enhanced the sensitivity in patients undergoing peritoneal dialysis from approximately 27 to 72 percent for AST and from 18 to 64 percent for ALT. We therefore use levels of 24 and 17 int. units/L for AST and ALT, respectively, as the upper limits of normal in patients on dialysis.</p><p class="headingAnchor" id="H4"><span class="h2">Gamma-glutamyl transpeptidase</span><span class="headingEndMark"> — </span>The serum concentration of GGT is usually normal in patients with end-stage kidney disease (ESKD) and the absence of liver disease. However, approximately 10 percent of patients with ESKD have unexplained elevations in serum GGT [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Alkaline phosphatase</span><span class="headingEndMark"> — </span>Plasma alkaline phosphatase activity can originate from liver, bone, intestine, or placenta; in most patients and normals, the majority of circulating activity consists of isoenzymes derived from either liver or bone. (See  <a class="medical medical_review" href="/z/d/html/3612.html" rel="external">"Enzymatic measures of hepatic cholestasis (alkaline phosphatase, 5'-nucleotidase, gamma-glutamyl transpeptidase)"</a> and  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p>Serum levels of alkaline phosphatase are elevated in many patients on dialysis because of concurrent renal osteodystrophy (see  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a>). The most reliable method of determining the tissue origin of the enzyme is polyacrylamide gel electrophoresis, a test that is not routinely performed in most clinical laboratories. Since bone-derived alkaline phosphatase is heat labile but liver derived is not, the source of elevated levels of this enzyme may be partially uncovered by the exposure of serum to elevated temperatures.</p><p>As a result, elevations in serum alkaline phosphatase alone in patients on dialysis only minimally suggest possible obstructive biliary disease. The possibility of hepatobiliary disease should be more seriously entertained if persistent elevations of this enzyme are found in conjunction with increased serum GGT or 5'-nucleotidase and if hyperparathyroidism has been excluded (see  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Elevated alkaline phosphatase'</a>). Retrospective studies have suggested a link between increased alkaline phosphatase and increased mortality in both peritoneal dialysis and hemodialysis populations. Possible mechanisms for this include poor bone health, increased vascular calcification, and higher levels of inflammation [<a href="#rid12">12</a>].</p><p>There are data to suggest that increased pre-ESKD alkaline phosphatase levels are linked to an increase in all-cause mortality post-ESKD when adjusted for liver disease and metabolic bone disease [<a href="#rid13">13</a>]. Increases in alkaline phosphatase in CKD stages 3 to 4 have also been shown to be associated with increases in all-cause mortality and ESKD [<a href="#rid14">14</a>]. It is unclear whether intervening to treat alkaline phosphatase levels would lead to improved outcomes in the CKD and ESKD population, and more research is warranted. </p><p class="headingAnchor" id="H6"><span class="h1">PANCREATIC ENZYMES</span><span class="headingEndMark"> — </span>Marked elevations of amylase and lipase are frequently used to help diagnose pancreatitis in patients without kidney failure (see  <a class="medical medical_review" href="/z/d/html/5652.html" rel="external">"Clinical manifestations and diagnosis of acute pancreatitis"</a>). However, serum concentrations of pancreatic amylase and lipase are elevated in patients with end-stage kidney disease (ESKD) in the absence of acute pancreatitis [<a href="#rid15">15-25</a>]. The highest levels of amylase and lipase are noted in patients on hemodialysis, but marked elevations can also be seen in patients with chronic kidney disease and in those undergoing peritoneal dialysis. A threefold to fivefold increase in amylase and lipase levels is most commonly observed, but the absolute values do not exceed <strong>three times</strong> the upper limit of normal. The degree of elevation is roughly proportional to the degree of kidney function impairment. (See  <a class="medical medical_review" href="/z/d/html/1897.html" rel="external">"Unique aspects of gastrointestinal disease in patients on dialysis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Amylase</span><span class="headingEndMark"> — </span>Elevations in serum amylase among patients with kidney failure or ESKD are most likely due to impaired kidney clearance. In one study, the serum amylase began to rise only when the creatinine clearance dropped below 50 mL/min [<a href="#rid23">23</a>].</p><p>The dialysis procedure alone does not appear to alter serum amylase. In one study, for example, no change was observed in serum amylase in samples obtained pre- and postdialysis [<a href="#rid17">17</a>]. However, these observations are confounded by the failure to correlate levels of amylase with variations in dialysis membrane clearance. In this study, one patient with acute pancreatitis had an increase in the P3 isoamylase band, a finding not observed in those without acute pancreatitis.</p><p>The use of <a class="drug drug_general" data-topicid="8769" href="/z/d/drug information/8769.html" rel="external">icodextrin</a> as an oncotic ultrafiltration stimulant in peritoneal dialysis may decrease measured serum amylase activity [<a href="#rid26">26,27</a>]. Based upon competition for enzymatic cleavage, icodextrin reduced measured amylase activity by 90 percent in one study of patients on peritoneal dialysis [<a href="#rid26">26</a>]. Lipase activity, however, was not affected. The serum amylase should not be used for the diagnosis of pancreatitis among patients utilizing icodextrin in their peritoneal dialysis regimen. Icodextrin and its metabolites are essentially completely cleared from the circulation by one week after discontinuation.</p><p class="headingAnchor" id="H8"><span class="h2">Lipase</span><span class="headingEndMark"> — </span>As with amylase, the elevations in serum lipase observed in patients with ESKD are most likely due to kidney function impairment. However, unlike amylase, the levels of lipase are also increased by the dialysis procedure itself [<a href="#rid17">17</a>].</p><p>The cause of increased serum lipase in postdialysis samples may be related to the use of heparin during dialysis. Consistent with this hypothesis is the observation that the postdialysis rise in serum lipase can be prevented by replacing heparin with alternate anticoagulants, nafamostat mesylate [<a href="#rid21">21</a>], and <a class="drug drug_general" data-topicid="83451" href="/z/d/drug information/83451.html" rel="external">defibrotide</a> [<a href="#rid28">28</a>].</p><p>The apparent heparin-induced postdialysis elevation in serum lipase may be attributable to the following properties of heparin:</p><p class="bulletIndent1"><span class="glyph">●</span>Lipolytic activity [<a href="#rid17">17</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Crossreactivity with lipoprotein lipase and hepatic triglyceride lipase [<a href="#rid21">21</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Ability to induce endothelial lipoprotein lipase [<a href="#rid28">28</a>]</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Trypsinogen</span><span class="headingEndMark"> — </span>Increased serum concentrations of trypsinogen have been observed in asymptomatic patients on dialysis or with nondialysis chronic kidney disease; it is therefore of diminished utility in these patients [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H3182694116"><span class="h1">SERUM CREATINE PHOSPHOKINASE (CPK)</span><span class="headingEndMark"> — </span>Creatine phosphokinase is degraded by the reticuloendothelial system. The level depends more on the amount of muscle damage and the half-life of the enzyme, rather than removal by the kidney.</p><p class="headingAnchor" id="H11"><span class="h1">CARDIAC ENZYMES</span><span class="headingEndMark"> — </span>Levels of cardiac enzymes are utilized to help assess the presence or absence of acute myocardial injury. Abnormal elevations in the serum concentrations of these enzymes may be the key diagnostic element in determining admission to the hospital and/or coronary care units. The principal cardiac enzymes are cardiac troponin T and cardiac troponin I (see  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>). Since coronary artery disease is highly prevalent in patients with end-stage kidney disease (ESKD), accurate interpretation of serum concentrations of these enzymes is extremely important.</p><p>A review of the evaluation and use of cardiac enzymes in patients with kidney failure is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1920.html" rel="external">"Cardiac troponins in patients with kidney disease"</a>.)</p><p class="headingAnchor" id="H263399866"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver enzymes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aminotransferases </strong>– Serum aminotransferase concentrations are commonly low normal in both patients on chronic dialysis and those with nondialysis chronic kidney disease. In order to increase the sensitivity of liver function tests among patients on dialysis, we use levels of 24 and 17 int. units/L for aspartate (AST) and alanine aminotransferase (ALT), respectively, as the upper limits of normal in patients on dialysis. (See <a class="local">'Liver enzymes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase </strong>– Ten percent of patients with end-stage kidney disease (ESKD) have unexplained elevations in serum GGT. Serum levels of alkaline phosphatase are elevated in many patients on dialysis because of concurrent renal osteodystrophy. Thus, isolated elevations in serum alkaline phosphatase only minimally suggests possible obstructive biliary disease in dialysis patients. Hepatobiliary disease is more strongly suggested by persistent elevations of alkaline phosphatase in conjunction with increased serum GGT or 5'-nucleotidase and if hyperparathyroidism has been excluded. (See <a class="local">'Liver enzymes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancreatic enzymes </strong>– Serum pancreatic amylase and lipase concentrations are <strong>elevated</strong> in patients with ESKD in the absence of acute pancreatitis. The degree of elevation is roughly proportional to the degree of kidney function impairment, but the absolute values do not exceed <strong>three times</strong> the upper limit of normal. Among patients on dialysis suspected of pancreatitis, a rise in serum amylase and/or lipase levels that is temporally associated with the onset of abdominal pain or is more than three times the upper limit of normal may be helpful. (See <a class="local">'Pancreatic enzymes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac enzymes</strong> – A review of the evaluation and use of cardiac enzymes in patients with kidney failure is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1920.html" rel="external">"Cardiac troponins in patients with kidney disease"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cohen GA, Goffinet JA, Donabedian RK, Conn HO. Observations on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 1976; 84:275.</a></li><li><a class="nounderline abstract_t">Nanji AA. Decreased activity of commonly measured serum enzymes: causes and clinical significance. Am J Med Technol 1983; 49:241.</a></li><li><a class="nounderline abstract_t">Guh JY, Lai YH, Yang CY, et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69:459.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001; 38:1009.</a></li><li><a class="nounderline abstract_t">Wolf PL, Williams D, Coplon N, Coulson AS. Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis. Clin Chem 1972; 18:567.</a></li><li><a class="nounderline abstract_t">Hamfelt A. The effect of pyridoxal phosphate on the aminotransferase assay in blood. Scand J Clin Lab Invest Suppl 1966; 18:Suppl 92:181.</a></li><li><a class="nounderline abstract_t">Rej R, Fasce CF Jr, Vanderlinde RE. Increased aspartate aminotransferase activity of serum after in vitro supplementation with pyridoxal phosphate. Clin Chem 1973; 19:92.</a></li><li><a class="nounderline abstract_t">Fabrizi F, Lunghi G, Andrulli S, et al. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol Dial Transplant 1997; 12:1394.</a></li><li><a class="nounderline abstract_t">Hung KY, Lee KC, Yen CJ, et al. Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B. Nephrol Dial Transplant 1997; 12:180.</a></li><li><a class="nounderline abstract_t">Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied. Clin Nephrol 2000; 54:151.</a></li><li><a class="nounderline abstract_t">Fine A, McIntosh WB. Elevation of serum gamma-glutamyl transpeptidase in end-stage chronic renal failure. Scott Med J 1975; 20:113.</a></li><li><a class="nounderline abstract_t">Rhee CM, Molnar MZ, Lau WL, et al. Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis. Perit Dial Int 2014; 34:732.</a></li><li><a class="nounderline abstract_t">Sumida K, Molnar MZ, Potukuchi PK, et al. Prognostic significance of pre-end-stage renal disease serum alkaline phosphatase for post-end-stage renal disease mortality in late-stage chronic kidney disease patients transitioning to dialysis. Nephrol Dial Transplant 2018; 33:264.</a></li><li><a class="nounderline abstract_t">Taliercio JJ, Schold JD, Simon JF, et al. Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population. Am J Kidney Dis 2013; 62:703.</a></li><li><a class="nounderline abstract_t">Royse VL, Jensen DM, Corwin HL. Pancreatic enzymes in chronic renal failure. Arch Intern Med 1987; 147:537.</a></li><li><a class="nounderline abstract_t">Bastani B, Mifflin TE, Lovell MA, et al. Serum amylases in chronic and end-stage renal failure: effects of mode of therapy, race, diabetes and peritonitis. Am J Nephrol 1987; 7:292.</a></li><li><a class="nounderline abstract_t">Vaziri ND, Chang D, Malekpour A, Radaht S. Pancreatic enzymes in patients with end-stage renal disease maintained on hemodialysis. Am J Gastroenterol 1988; 83:410.</a></li><li><a class="nounderline abstract_t">Lin XZ, Chen TW, Wang SS, et al. Pancreatic enzymes in uremic patients with or without dialysis. Clin Biochem 1988; 21:189.</a></li><li><a class="nounderline abstract_t">Caruana RJ, Altman R, Fowler B, et al. Correlates of amylase and lipase levels in chronic dialysis patients. Int J Artif Organs 1988; 11:454.</a></li><li><a class="nounderline abstract_t">Kimmel PL, Tenner S, Habwe VQ, et al. Trypsinogen and other pancreatic enzymes in patients with renal disease: a comparison of high-efficiency hemodialysis and continuous ambulatory peritoneal dialysis. Pancreas 1995; 10:325.</a></li><li><a class="nounderline abstract_t">Shibasaki T, Matsuda H, Ohno I, et al. Significance of serum lipase in patients undergoing hemodialysis. Am J Nephrol 1996; 16:309.</a></li><li><a class="nounderline abstract_t">Masoero G, Bruno M, Gallo L, et al. Increased serum pancreatic enzymes in uremia: relation with treatment modality and pancreatic involvement. Pancreas 1996; 13:350.</a></li><li><a class="nounderline abstract_t">Collen MJ, Ansher AF, Chapman AB, et al. Serum amylase in patients with renal insufficiency and renal failure. Am J Gastroenterol 1990; 85:1377.</a></li><li><a class="nounderline abstract_t">Jiang CF, Ng KW, Tan SW, et al. Serum level of amylase and lipase in various stages of chronic renal insufficiency. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 65:49.</a></li><li><a class="nounderline abstract_t">Robitaille R, Lafrance JP, Leblanc M. Altered laboratory findings associated with end-stage renal disease. Semin Dial 2006; 19:373.</a></li><li><a class="nounderline abstract_t">Schoenicke G, Grabensee B, Plum J. Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity. Nephrol Dial Transplant 2002; 17:1988.</a></li><li><a class="nounderline abstract_t">Anderstam B, García-López E, Heimbürger O, Lindholm B. Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid. Perit Dial Int 2003; 23:146.</a></li><li><a class="nounderline abstract_t">Montalto G, Soresi M, Carroccio A, et al. Influence of haemodialysis on lipase activity. Eur J Clin Chem Clin Biochem 1997; 35:237.</a></li></ol></div><div id="topicVersionRevision">Topic 1895 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1259262" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Observations on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6189394" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Decreased activity of commonly measured serum enzymes: causes and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7777113" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684554" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5026769" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5958519" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The effect of pyridoxal phosphate on the aminotransferase assay in blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4683373" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increased aspartate aminotransferase activity of serum after in vitro supplementation with pyridoxal phosphate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9249775" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9157333" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968693" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/242073" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Elevation of serum gamma-glutamyl transpeptidase in end-stage chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24385335" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28064159" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prognostic significance of pre-end-stage renal disease serum alkaline phosphatase for post-end-stage renal disease mortality in late-stage chronic kidney disease patients transitioning to dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23769134" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2435254" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pancreatic enzymes in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2446498" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Serum amylases in chronic and end-stage renal failure: effects of mode of therapy, race, diabetes and peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2450453" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pancreatic enzymes in patients with end-stage renal disease maintained on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2455611" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pancreatic enzymes in uremic patients with or without dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2462548" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Correlates of amylase and lipase levels in chronic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7540759" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Trypsinogen and other pancreatic enzymes in patients with renal disease: a comparison of high-efficiency hemodialysis and continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8739284" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Significance of serum lipase in patients undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8899795" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Increased serum pancreatic enzymes in uremia: relation with treatment modality and pancreatic involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1699413" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Serum amylase in patients with renal insufficiency and renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12014357" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Serum level of amylase and lipase in various stages of chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16970737" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Altered laboratory findings associated with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401858" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12713081" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9127746" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Influence of haemodialysis on lipase activity.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
